Table 2 The comparison of the baseline characteristics between the ADA-positive and ADA-negative groups
ADA-positive group (n = 6) | ADA-negative group (n = 22) | p value | |
|---|---|---|---|
Age (years) | 69 (66.3–77.5) | 71 (62.5–77) | 0.89 |
Gender (male/female), n | 2/4 | 5/17 | 0.48 |
Body weight (kg) | 57.5 (44.8–64.7) | 51.3 (46.9–55) | 0.4 |
Disease duration (years) | 20 (15–32.8) | 17.5 (11.8–27) | 0.4 |
Prior IFX treatment duration (months) | 102.5 (69.5–127.3) | 115.5 (93.8–134.8) | 0.45 |
ESR (mm/h) | 27 (12.5–47.5) | 20.5 (14.5–33.3) | 0.61 |
CRP (mg/dL) | 0.5 (0.1–1.1) | 0.1 (0.04–0.5) | 0.29 |
MMP-3 (ng/ml) | 91.4 (25.8–211.8) | 80.2 (46–118.2) | 0.91 |
DAS28 | 2.8 (1.9–3.8) | 3.0 (2.4–3.2) | 0.78 |
RF (IU/ml) | 114.5 (41.3–277.3) | 30 (10.5–71) | 0.03 |
ACPA (U/ml) | 183.4 (50.2–330) | 57.6 (19.9–147.5) | 0.18 |